Charles Swanton
查尔斯·斯万顿
PhD, FRCP, FMedSci, FRS
Chief Scientist, Cancer Research UK; Professor of Cancer Medicine, UCL; Group Leader, Francis Crick Institute英国癌症研究首席科学家；伦敦大学学院癌症医学教授；弗朗西斯·克里克研究所团队负责人
👥Biography 个人简介
Charles Swanton is the world's leading authority on cancer evolution and intratumor heterogeneity. He founded and leads TRACERx, the landmark prospective study tracking the evolutionary trajectory of non-small cell lung cancer from diagnosis to recurrence. His work using multiregion sequencing has revealed how Darwinian clonal evolution drives treatment resistance and metastasis.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
TRACERx — Cancer Evolutionary Trajectory Study
Founded and leads TRACERx, prospectively sequencing 842 NSCLC patients across multiple tumor regions and longitudinal blood samples to map clonal evolution, metastatic seeding, and resistance mechanisms in real time.
Intratumor Heterogeneity and Clonal Evolution
Demonstrated through multiregion sequencing that the extent of intratumor genetic heterogeneity predicts poor prognosis and immune evasion in renal cell carcinoma and lung cancer, redefining cancer biology.
ctDNA as Early Relapse Biomarker in NSCLC
Showed that circulating tumor DNA from multiregion tumor-informed panels can detect minimal residual disease and predict relapse months before radiological recurrence, establishing ctDNA as a clinical tool.
Representative Works 代表性著作
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing
New England Journal of Medicine (2012)
Demonstrated extensive branched evolutionary genomic heterogeneity within primary renal cell carcinomas using multiregion sequencing, challenging single-biopsy tumor sampling paradigms.
Tracking the evolution of non–small-cell lung cancer
New England Journal of Medicine (2017)
First TRACERx analysis of 100 NSCLC patients demonstrating clonal heterogeneity correlates with genomic instability and recurrence risk, establishing the cancer evolution framework in clinical oncology.
Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution
Nature (2017)
Demonstrated tumor-informed ctDNA profiling detects minimal residual disease post-surgery and predicts relapse, providing the basis for ctDNA-guided adjuvant therapy trials.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 查尔斯·斯万顿 的研究动态
Follow Charles Swanton's research updates
留下邮箱，当我们发布与 Charles Swanton（The Francis Crick Institute / University College London）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment